{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:02:01Z","timestamp":1793898121801,"version":"4.8.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,2]],"date-time":"2020-02-02T00:00:00Z","timestamp":1580601600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004628","name":"MedImmune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004830","name":"Siemens","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004830","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","award":["267806"],"award-info":[{"award-number":["267806"]}],"id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","award":["27127"],"award-info":[{"award-number":["27127"]}],"id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001610","name":"Falk Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001610","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016915","name":"Inventiva Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018952","name":"Birmingham Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018952","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1053\/j.gastro.2020.01.043","type":"journal-article","created":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T03:36:32Z","timestamp":1580787392000},"page":"1611-1625.e12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1016,"title":["Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis"],"prefix":"10.1053","volume":"158","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3043-6011","authenticated-orcid":false,"given":"Rod S.","family":"Taylor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca J.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3025-9323","authenticated-orcid":false,"given":"Sue","family":"Bayliss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8474-1759","authenticated-orcid":false,"given":"Hannes","family":"Hagstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrik","family":"Nasr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorn M.","family":"Schattenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Ishigami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2215-9410","authenticated-orcid":false,"given":"Vincent","family":"Wai-Sun Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noam","family":"Peleg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7437-9381","authenticated-orcid":false,"given":"Amir","family":"Shlomai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2655-8283","authenticated-orcid":false,"given":"Giada","family":"Sebastiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Seko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2502-1177","authenticated-orcid":false,"given":"Neeraj","family":"Bhala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zobair M.","family":"Younossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9518-0088","authenticated-orcid":false,"given":"Quentin M.","family":"Anstee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5638-2453","authenticated-orcid":false,"given":"Stuart","family":"McPherson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6085-3652","authenticated-orcid":false,"given":"Philip N.","family":"Newsome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2020.01.043_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2020.01.043_bib2","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1002\/hep.20973","article-title":"Nonalcoholic fatty liver disease: from steatosis to cirrhosis","volume":"43","author":"Farrell","year":"2006","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2020.01.043_bib3","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/hep.27173","article-title":"FLIP Pathology Consortium. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease","volume":"60","author":"Bedossa","year":"2014","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2020.01.043_bib4","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.jhep.2014.11.034","article-title":"Evidence of NAFLD. Progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis & clinical management","volume":"62","author":"McPherson","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2020.01.043_bib5","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2020.01.043_bib6","first-page":"756","article-title":"Nonalcoholic steatohepatitis and endpoints in clinical trials","volume":"12","author":"Hannah","year":"2016","journal-title":"Gastroenterol & Hepatol"},{"key":"10.1053\/j.gastro.2020.01.043_bib7","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/nrd.2016.81","article-title":"Use of surrogate end points in healthcare policy: a proposal for adoption of a validation framework","volume":"15","author":"Ciani","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1053\/j.gastro.2020.01.043_bib8","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2020.01.043_bib9","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1002\/hep.29388","article-title":"Comments on \u201cIncreased Risk of Mortality by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis\u201d","volume":"66","author":"Safiri","year":"2017","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2020.01.043_bib10","doi-asserted-by":"crossref","first-page":"i1981","DOI":"10.1136\/bmj.i1981","article-title":"Sparse data bias: a problem hiding in plain sight","volume":"352","author":"Greenland","year":"2016","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2020.01.043_bib11","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1053\/j.gastro.2020.01.043_bib12","doi-asserted-by":"crossref","first-page":"427","DOI":"10.7326\/0003-4819-144-6-200603210-00010","article-title":"Evaluation of the quality of prognosis studies in systematic reviews","volume":"144","author":"Hayden","year":"2006","journal-title":"Ann Inter Med"},{"key":"10.1053\/j.gastro.2020.01.043_bib13","doi-asserted-by":"crossref","first-page":"h870","DOI":"10.1136\/bmj.h870","article-title":"Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients","volume":"350","author":"Iorio","year":"2015","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2020.01.043_bib14","unstructured":"Higgins JPT, Thomas J, Chandler J, et\u00a0al, eds. Cochrane handbook for systematic reviews of interventions, version 6.0. https:\/\/training.cochrane.org\/handbook. Updated August 2019. Accessed December 30,\u00a02019."},{"key":"10.1053\/j.gastro.2020.01.043_bib15","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2020.01.043_bib16","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1017\/S0266462314000300","article-title":"Validation of surrogate endpoints in advanced solid tumours: systematic review of statistical methods, results, and implications for policy makers","volume":"30","author":"Ciani","year":"2014","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1053\/j.gastro.2020.01.043_bib17","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/pst.207","article-title":"Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation","volume":"5","author":"Burzykowski","year":"2006","journal-title":"Pharm Stat"},{"key":"10.1053\/j.gastro.2020.01.043_bib18","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.24491","article-title":"The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study","volume":"54","author":"Bhala","year":"2011","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2020.01.043_bib19","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/hep.22868","article-title":"Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research network","volume":"49","author":"David","year":"2009","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2020.01.043_bib20","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD","volume":"67","author":"Hagstr\u00f6m","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2020.01.043_bib21","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hep4.1124","article-title":"Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: a long-term follow-up study","volume":"2","author":"Hagstr\u00f6m","year":"2017","journal-title":"Hepatol Commun"},{"key":"10.1053\/j.gastro.2020.01.043_bib22","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/j.cgh.2018.12.016","article-title":"Health-related quality of life in non-alcoholic fatty liver disease associates with hepatic inflammation","volume":"17","author":"Huber","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2020.01.043_bib23","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/jgh.14448","article-title":"Utility and limitations of noninvasive fibrosis markers for predicting prognosis in biopsy-proven Japanese non-alcoholic fatty liver disease patients","volume":"34","author":"Ito","year":"2019","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2020.01.043_bib24","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/hep.28697","article-title":"Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients","volume":"65","author":"Leung","year":"2017","journal-title":"Hepatology"},{"issue":"8","key":"10.1053\/j.gastro.2020.01.043_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0202393","article-title":"Noninvasive scoring systems predict hepatic and extra-hepatic cancers in patients with nonalcoholic fatty liver disease","volume":"13","author":"Peleg","year":"2018","journal-title":"PLoS One"},{"issue":"6","key":"10.1053\/j.gastro.2020.01.043_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128774","article-title":"Prognostic value of non-invasive fibrosis and steatosis tools, hepatic venous pressure gradient (HVPG) and histology in nonalcoholic steatohepatitis","volume":"10","author":"Sebastiani","year":"2015","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2020.01.043_bib27","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/hepr.12407","article-title":"Predictors of malignancies and overall mortality in Japanese patients with biopsy-proven non-alcoholic fatty liver disease","volume":"45","author":"Seko","year":"2015","journal-title":"Hepatol Res"},{"key":"10.1053\/j.gastro.2020.01.043_bib28","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/j.gastro.2018.04.034","article-title":"Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study","volume":"155","author":"Vilar-Gomez","year":"2018","journal-title":"Gastroenterol"},{"key":"10.1053\/j.gastro.2020.01.043_bib29","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1002\/hep.24268","article-title":"Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality","volume":"53","author":"Younossi","year":"2011","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2020.01.043_bib30","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/hep4.1054","article-title":"Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease","volume":"1","author":"Younossi","year":"2017","journal-title":"Hepatol Commun"},{"key":"10.1053\/j.gastro.2020.01.043_bib31","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1111\/liv.13706","article-title":"Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib","volume":"38","author":"Younossi","year":"2018","journal-title":"Liver Int"},{"key":"10.1053\/j.gastro.2020.01.043_bib32","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/j.cgh.2019.01.001","article-title":"Validation of Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis in patients with biopsy-proven nonalcoholic steatohepatitis","volume":"17","author":"Younossi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1053\/j.gastro.2020.01.043_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175717","article-title":"A\u00a0randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis","volume":"12","author":"McPherson","year":"2017","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2020.01.043_bib34","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"9972","key":"10.1053\/j.gastro.2020.01.043_bib35","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2020.01.043_bib38","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jhep.2019.04.019","article-title":"Report on the AASLD\/EASL joint workshop on clinical trial endpoints in NAFLD","volume":"71","author":"Rinella","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2020.01.043_bib39","first-page":"219","article-title":"Controversies in the diagnosis and management of NAFLD and NASH","volume":"10","author":"Rinella","year":"2014","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"10.1053\/j.gastro.2020.01.043_bib40","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.jchf.2018.03.017","article-title":"Validation of exercise capacity as a surrogate endpoint in exercise-based rehabilitation for heart failure: a meta-analysis of randomized controlled trials","volume":"6","author":"Ciani","year":"2018","journal-title":"JACC Heart Fail"},{"issue":"42","key":"10.1053\/j.gastro.2020.01.043_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta16420","article-title":"Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses","volume":"16","author":"Pavey","year":"2012","journal-title":"Health Technol Assess"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508520301372?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508520301372?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:46:55Z","timestamp":1762163215000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508520301372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0016508520301372"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2020.01.043","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2020.01.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the AGA Institute. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}